The IDWeek Program Committee is seeking reviewers for the IDWeek abstract review process. You can help by volunteering to review abstracts in your area of expertise! The success of the peer review process depends on the willingness of qualified reviewers to share their time and expertise.
Reviewers will be asked to review 20-35 abstracts, and either participate in a (up-to) 30 min conference call or provide recommendations electronically. Please note, the final decisions regarding reviewers will be made by the IDWeek Chairs and will be determined by actual number of submissions in a respective category and where additional reviewers may be needed. Abstract reviewers should have specific expertise in the content they evaluate as well as a broad knowledge of infectious diseases and infection prevention. Reviews must be performed in an unbiased fashion that is conscientious of the wide spectrum of participants of IDWeek.
Abstract Reviewer Criteria:
- must have first-authored or senior-authored two or more peer-reviewed original manuscripts
- must be two or more years out of training (must have completed by 2023 or later)
Responsibilities
- Review assigned abstracts in a timely manner
- Participate in a conference call or provide recommendations electronically
Estimated Time Commitment
15 hours (will depend on number of abstracts assigned)
IDWeek 2026 Abstract Timeline*
May 1: Abstract Submission Deadline
May 6-26: Online Abstract Review
May 29-June 6: Abstract Review Conference Calls with Category Groups
Aug. 5: Late Breaker Abstracts Submission Deadline
Aug. 11-Sept. 2: Late Breaker Abstracts Review
*Dates are subject to change
IDWeek Abstract Subject Categories
A: Antimicrobial Agents Including Antibacterial, Antiviral, and Antifungal Drugs
A1. Novel agents
A2. Pharmacokinetics and Pharmacodynamics studies
A3. Resistance mechanisms
A4. Treatment of antimicrobial resistant infections
A5. Pharmacogenetics
A6. New drug development (formerly L3)
B: Basic Science and Translational Studies of Microbial Pathogenesis and Infectious Diseases
B1. Studies of correlates of protection (or biomarkers) against microbial infection and disease in patients or experimental models
B2. Studies of the immune response to microbial infection and disease in patients or experimental models
B3. Studies of genetic factors that govern susceptibility to microbial infection and disease
B4. Studies of microbial factors that govern susceptibility to microbial infection and disease
B5. Studies at the interface of host-microbe interaction
B6. Microbiome science
C: Clinical Infectious Diseases
C1. Clinical trials
C2. Bone and joint
C3. Skin and soft tissue
C4. Respiratory infections - viral
C5. Respiratory infections - bacterial
C6. Enteric infection
C7. Bacteremia
C8. Endocarditis
C9. CNS infection
C10. Sexually transmitted infections
C11. UTIs
C12. Social determinants of health
D: Infectious Disease Diagnostics
D1. Bacteriology/mycobacteriology
D2. Virology
D3. Parasitology
D4. Mycology
D5. Typing/sequencing
D6. New diagnostics (formerly L2)
D7. Other (e.g., host response biomarkers, molecular imaging, metabolomics/proteomics, etc.)
E: Infectious Diseases Medical Education (scholarly work directed at enhancing infectious diseases education of trainees and/or health professionals, social determinants of health)
F: Hepatitis (all HIV co-infection abstracts should be submitted to Category H)
F1. Hepatitis A
F2. Hepatitis B
F3. Hepatitis C
F4. Hepatitis E
G: Global Health (e.g., travel medicine, tropical medicine and parasitology, endemic/epidemic diseases of resource-challenged areas, social determinants of health)
H: HIV/AIDS, other retroviruses, and co-infections
H1. Epidemiology and screening
H2. Prevention
H3. Pathogenesis
H4. Treatment
H5. Complications and co-infections
H6. Social determinants of health
I: Adult and Pediatric Vaccines
I1. Adult vaccines
I2. Pediatric vaccines
I3. Adolescent vaccines
I4. New vaccines (formerly L3)
J: Clinical Practice Issues
J1. Billing/Coding
J2. Medical Records & Informatics
J3. Healthcare Reform
J4. Home Health/OPAT
J5. Quality Improvement
J6. ID Workforce/Value of ID
J7. Telehealth
J8. Long Term Care (SNF/LTACH)
K: Tuberculosis and other Mycobacterial Infections
M: Medical Mycology
M1. Clinical studies of fungal infections
M2. Studies of fungal pathogenesis in patients with immune impairment
M3. Studies of the pathogenesis of fungal infections
N: Healthcare Epidemiology and Prevention
N1. HAI: Occupational infection prevention
N2. HAI: Surveillance
N3. HAI: Epidemiologic methods
N4. HAI: Device-associated (CLABSI, CAUTI, VAP)
N5. HAI: Disinfection/sterilization & environmental infection prevention
N6. HAI: Hand hygiene/transmission-based precautions
N7. HAI: Surgical site infections
N8. HAI: C. difficile
N9. HAI: Gram-positives (MRSA, MSSA, VRE)
N10. HAI: Gram-negatives (MDR-GNR)
N11. HAI: Outbreaks
N12. HAI: Non-acute care
N13. HAI: Non-bacterial (fungal, viral)
N14. Social determinants of health
O: Public Health (Studies on issues pertaining to preparedness for and response to outbreaks of infectious diseases including those linked to agents of bioterror, foodborne, waterborne, vector borne, and zoonotic diseases, vaccine-preventable diseases and social determinants of health)
P: Pediatric and Perinatal Infections
P1. Pediatric bacterial studies (natural history and therapeutic)
P2. Pediatric fungal studies (natural history and therapeutic)
P3. Pediatric viral studies (natural history and therapeutic)
P4. Pediatric antimicrobial stewardship (inpatient/outpatient pediatric focused)
P5. Pediatric healthcare-associated infection epidemiology and prevention
P6. Pediatric HIV
P7. Pediatric maternal-child infections
P8. Social determinants of health
S: Antimicrobial Stewardship, including quality of care
S1. Antibiotic stewardship: Program development & evaluation
S2. Antibiotic stewardship: Outcomes Assessment (Clinical and Economic)
S3. Antibiotic stewardship: Diagnostics/diagnostic stewardship
S4. Antibiotic stewardship: Special populations
S5. Antibiotic stewardship: Non-inpatient settings
S6. Antibiotic stewardship: Trends in antimicrobial prescribing
S7. Social determinants of health
T: Transplant and Immunocompromised Host Infections
T1. Studies of pre-transplant screening and evaluation
T2. Studies of empiric and pre-emptive therapy
T3. Studies of the epidemiology of infections in transplant patients and patients with impaired immunity due to underlying disease or immunosuppressive drugs
T4. Social determinants of health
V: Virology (all viruses other than HIV, HIV co-infections, and hepatitis)
V1. Studies of the epidemiology of viral infections
V2. Studies of viral pathogenesis
V3. Studies of treatment and prevention of viral infections
Y: Career and Professional Development in ID
Y1. Structural determinants and career advancement (Inclusion, Diversity, Access and Equity)
Y2. Leadership development
Y3. Policy and advocacy
Y4. Ethics, publishing, and other academic/professional affairs
Y5. Structural equity (Inclusion, Diversity, Access and Equity)
Z: COVID-2019 and co-infections
Z1. Epidemiology and screening
Z2. Infection prevention
Z3. Pathogenesis
Z4. Treatment
Z5. Complications, co-infections, and clinical outcomes
Z6. Diagnostics
Z7. Research
Z8. Global response/response in low resource settings
Z9. Special populations (e.g. pregnant women, children, immunocompromised, etc)
Z10. Impact of social distancing/mitigation measures
Z11. Vaccines
Z12. Social determinants of health
Z13. Other